NNM Securities

COMPANY
more from company profile
HomeMarket Info Company Profile Smart Quotes

Smart Quotes

AUROBINDO PHARMA LTD.

NSE : AUROPHARMABSE : 524804ISIN CODE : INE406A01037Industry : Pharmaceuticals & DrugsHouse : Aurobindo
BSE614.350.9 (+0.15 %)
PREV CLOSE ( ) 613.45
OPEN PRICE ( ) 615.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 121918
TODAY'S LOW / HIGH ( )603.75 618.40
52 WK LOW / HIGH ( )527.05 808.95
NSE613.850 (0 %)
PREV CLOSE( ) 613.85
OPEN PRICE ( ) 614.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 613.85 (2192)
VOLUME 2309757
TODAY'S LOW / HIGH( ) 603.20 618.55
52 WK LOW / HIGH ( )527 809.45
BSE
1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Incorporation Year : 26-12 1986
Management Info
K Ragunathan - Chairman N Govindarajan - Managing Director
Registered Office

Address Plot No. 2,Maitrivihar ,Ameerpet,
Hyderabad,
Telangana-500038

Phone +91-040-66725000

Email info@aurobindo.com

Website www.aurobindo.com

Registrars Details
Karvy Computershare Pvt Ltd
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
 Listing : BSE, NSE, MCX
NEWS
18Jun Aurobindo Pharma informs about audited
With reference to the letter dated 28th May, 2018 wherein the company ha..
08Jun Aurobindo Pharma receives USFDA’s appr
Aurobindo Pharma has received final approval from the US Food & Drug..
08Jun Announcement under Regulation 30 (LOD
Aurobindo Pharma receives USFDA Approval for Omeprazole DR Tablets OTC..
28May Aurobindo Pharma informs about analyst
Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure..
16May Board Meeting To Consider The Audited
We hereby inform pursuant to Regulation 29 of the SEBI (Listing Obligati..
MORE
Financials
Rs. in Millions
QTR Mar 18 ANNUAL 18
Net Profit3082.918127.7
Gross Profit 3752.8 23429.4
Operating Profit 4842.427506.6
Net Sales 23547.2103031.5
MORE
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group
Abbott India (BSE)
 6682.00 (2.23%)
M.Cap (Rs. in Cr)14198.78
Astrazeneca Pharma I (BSE)
 1415.45 (8.28%)
M.Cap (Rs. in Cr)3538.63
Glaxosmithkline Phar (BSE)
 2800.75 (2.05%)
M.Cap (Rs. in Cr)23723.20
Merck (BSE)
 2433.20 (2.13%)
M.Cap (Rs. in Cr)4038.96
SMS Lifesciences (BSE)
 386.70 (14.44%)
M.Cap (Rs. in Cr)116.91
MORE
Shareholding Pattern
PROMOTERS 51.87%
MUTUAL FUNDS/UTI 15.06%
NON-INSTITUTION 14.5%
FI/BANKS/INSURANCE 0.57%
GOVERNMENT 0%
FII 0%
MORE
Mf Holdings
MORE
ATTENTION INVESTORSKYCIPO
TERMS & CONDITIONS| PRIVACY POLICY| DISCLAIMER| DISCLOSURE| SEBI| FMC| NSE| BSE| MCX
REGISTRATION NOS.

NSE CM-INB231215030|NSE F& O - INF231215030, NSE CD-INE231215030, BSE CM–INB011215036 |BSE F & O - INF011215036 MCX-SX CM-INB261215033|MCX-SX F & O - INF261215033|MCX-SX CD-INE261215033 NSDL - IN-DP-NSDL-319-2009ROC REG - 21-097912

INVESTOR PROTECTION

Compliance officer : Aishwarya M. Kalal, Tel no: 022-40790032, Mobile no- 9773104340, E-mail id- Complaince@nnmsecurities.com

Investor grievance : support@nnmsecurities.com

Copyright © 2016 NNM Securities.com

Designed , Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.